Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Cisplatin + Gemcitabine in Advanced NSCLC (PS 2)
NCT00526643Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Dec 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Nov 2007; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00526643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526643.